What is GlucoTrack Financial Strength?
GlucoTrack has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
GuruFocus does not calculate GlucoTrack's interest coverage with the available data.
As of today, GlucoTrack's Altman Z-Score is 0.00.
Competitive Comparison of GlucoTrack's Financial Strength
For the Medical Instruments & Supplies subindustry, GlucoTrack's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlucoTrack's Financial Strength Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, GlucoTrack's Financial Strength distribution charts can be found below:
* The bar in red indicates where GlucoTrack's Financial Strength falls into.
GlucoTrack Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
GlucoTrack's Interest Expense for the
months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-2.42 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.20 Mil.
GlucoTrack's Interest Coverage for the quarter that ended in Dec. 2023 is
| GuruFocus does not calculate GlucoTrack's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
GlucoTrack's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
GlucoTrack has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlucoTrack (GlucoTrack) Business Description
Traded in Other Exchanges
N/A
Address
301 Route 17 North, Suite 800, Rutherford, New Jersey, NJ, USA, 07070
GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It also focuses on developing a wireless module for transmission of measurement data captured by the GlucoTrack model DF-F to a cloud-based server.
Executives
| James S Cardwell |
officer: Chief Financial Officer |
CLINTON SQUARE, 75 S. CLINTON AVE., SUITE 510, ROCHESTER NY 14604 |
| Erin Catherine Carter |
director |
301 RTE 17 NORTH, STE. 800, RUTHERFORD NJ 07070 |
| Allen Danzig |
director |
301 RT 17 NORTH, SUITE 800, RUTHERFORD NJ 07070 |
| Shimon D Rapps |
director |
C/O ANDREW GARRETT, INC., 52 VANDERBILT AVENUE SUITE 510, NEW YORK NY 10017 |
| Drew Sycoff |
director |
C/O ANDREW GARRETT INC, 52 VANDERBILT AVENUE - 20TH FLOOR, NEW YORK NY 10017 |
| David Podwalski |
officer: Chief Commercial Officer |
19 HA'YAHALOMIM ST., P.O. BOX 12163, ASHDOD L3 7760049 |
| Michael Hauck |
director |
19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049 |
| John A Graham |
director, officer: Chief Executive Officer |
19 HA'YAHALOMIM STREET, P.O. BOX 12163, ASHDOD L3 7760049 |
| Sami Sassoun |
officer: Chief Financial Officer |
39-06 ACKERMAN DRIVE, FAIR LAWN L3 7760049 |
| Philip Darivoff |
director |
1 FARMSTEAD ROAD, SHORT HILLS NJ 07078 |
| Revan Schwartz |
director |
19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049 |
| Angela Strand Boydston |
director |
C/O AEROGEN, INC., 2071 STIERLIN COURT, MOUNTAIN VIEW CA 94043 |
| Leslie Seff |
director |
PO BOX 59, 40 HELLBROOK LANE, ULSTER PARK NY 12487 |
| Eran Hertz |
officer: Chief Financial Officer |
C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L3 78100 |
| Israel B. Ehrlich |
director |
C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L378100 |
GlucoTrack (GlucoTrack) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GCTK has been successfully added to your